Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C

Craig A. Belon, David N. Frick

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

The hepatitis C virus (HCV) leads to chronic liver disease and affects more than 2% of the world's population. Complications of the disease include fibrosis, cirrhosis and hepatocellular carcinoma. Current therapy for chronic HCV infection, a combination of ribavirin and pegylated IFN-α, is expensive, causes profound side effects and is only moderately effective against several common HCV strains. Specifically targeted antiviral therapy for hepatitis C (STAT-C) will probably supplement or replace present therapies. Leading compounds for STAT-C target the HCV nonstructural (NS)5B polymerase and NS3 protease, however, owing to the constant threat of viral resistance, other targets must be continually developed. One such underdeveloped target is the helicase domain of the HCV NS3 protein. The HCV helicase uses energy derived from ATP hydrolysis to separate based-paired RNA or DNA. This article discusses unique features of the HCV helicase, recently discovered compounds that inhibit HCV helicase catalyzed reactions and HCV cellular replication, and new methods to monitor helicase action in a high-throughput format.

Original languageEnglish (US)
Pages (from-to)277-293
Number of pages17
JournalFuture Virology
Volume4
Issue number3
DOIs
StatePublished - Oct 23 2009
Externally publishedYes

Fingerprint

Hepatitis C
Hepacivirus
Antiviral Agents
Therapeutics
Fibrosis
Ribavirin
Chronic Hepatitis C
Virus Diseases
Virus Replication
Liver Diseases
Hepatocellular Carcinoma
Hydrolysis
Peptide Hydrolases
Chronic Disease
Adenosine Triphosphate
RNA
DNA
Population

Keywords

  • ATPase
  • DNA
  • HCV
  • Helicase
  • Motor protein
  • Protease
  • RNA
  • STAT-C

ASJC Scopus subject areas

  • Virology

Cite this

Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C. / Belon, Craig A.; Frick, David N.

In: Future Virology, Vol. 4, No. 3, 23.10.2009, p. 277-293.

Research output: Contribution to journalReview article

@article{92fd3077d93c4987a9f8c8eced378415,
title = "Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C",
abstract = "The hepatitis C virus (HCV) leads to chronic liver disease and affects more than 2{\%} of the world's population. Complications of the disease include fibrosis, cirrhosis and hepatocellular carcinoma. Current therapy for chronic HCV infection, a combination of ribavirin and pegylated IFN-α, is expensive, causes profound side effects and is only moderately effective against several common HCV strains. Specifically targeted antiviral therapy for hepatitis C (STAT-C) will probably supplement or replace present therapies. Leading compounds for STAT-C target the HCV nonstructural (NS)5B polymerase and NS3 protease, however, owing to the constant threat of viral resistance, other targets must be continually developed. One such underdeveloped target is the helicase domain of the HCV NS3 protein. The HCV helicase uses energy derived from ATP hydrolysis to separate based-paired RNA or DNA. This article discusses unique features of the HCV helicase, recently discovered compounds that inhibit HCV helicase catalyzed reactions and HCV cellular replication, and new methods to monitor helicase action in a high-throughput format.",
keywords = "ATPase, DNA, HCV, Helicase, Motor protein, Protease, RNA, STAT-C",
author = "Belon, {Craig A.} and Frick, {David N.}",
year = "2009",
month = "10",
day = "23",
doi = "10.2217/fvl.09.7",
language = "English (US)",
volume = "4",
pages = "277--293",
journal = "Future Virology",
issn = "1746-0794",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C

AU - Belon, Craig A.

AU - Frick, David N.

PY - 2009/10/23

Y1 - 2009/10/23

N2 - The hepatitis C virus (HCV) leads to chronic liver disease and affects more than 2% of the world's population. Complications of the disease include fibrosis, cirrhosis and hepatocellular carcinoma. Current therapy for chronic HCV infection, a combination of ribavirin and pegylated IFN-α, is expensive, causes profound side effects and is only moderately effective against several common HCV strains. Specifically targeted antiviral therapy for hepatitis C (STAT-C) will probably supplement or replace present therapies. Leading compounds for STAT-C target the HCV nonstructural (NS)5B polymerase and NS3 protease, however, owing to the constant threat of viral resistance, other targets must be continually developed. One such underdeveloped target is the helicase domain of the HCV NS3 protein. The HCV helicase uses energy derived from ATP hydrolysis to separate based-paired RNA or DNA. This article discusses unique features of the HCV helicase, recently discovered compounds that inhibit HCV helicase catalyzed reactions and HCV cellular replication, and new methods to monitor helicase action in a high-throughput format.

AB - The hepatitis C virus (HCV) leads to chronic liver disease and affects more than 2% of the world's population. Complications of the disease include fibrosis, cirrhosis and hepatocellular carcinoma. Current therapy for chronic HCV infection, a combination of ribavirin and pegylated IFN-α, is expensive, causes profound side effects and is only moderately effective against several common HCV strains. Specifically targeted antiviral therapy for hepatitis C (STAT-C) will probably supplement or replace present therapies. Leading compounds for STAT-C target the HCV nonstructural (NS)5B polymerase and NS3 protease, however, owing to the constant threat of viral resistance, other targets must be continually developed. One such underdeveloped target is the helicase domain of the HCV NS3 protein. The HCV helicase uses energy derived from ATP hydrolysis to separate based-paired RNA or DNA. This article discusses unique features of the HCV helicase, recently discovered compounds that inhibit HCV helicase catalyzed reactions and HCV cellular replication, and new methods to monitor helicase action in a high-throughput format.

KW - ATPase

KW - DNA

KW - HCV

KW - Helicase

KW - Motor protein

KW - Protease

KW - RNA

KW - STAT-C

UR - http://www.scopus.com/inward/record.url?scp=70350102158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350102158&partnerID=8YFLogxK

U2 - 10.2217/fvl.09.7

DO - 10.2217/fvl.09.7

M3 - Review article

AN - SCOPUS:70350102158

VL - 4

SP - 277

EP - 293

JO - Future Virology

JF - Future Virology

SN - 1746-0794

IS - 3

ER -